Senseonics Holdings Inc

SENS

Market cap $293M

Senseonics shares gain after Eversense 365 became the first one-year implantable CGM integrated with an automated insulin delivery system.

twiist™ becomes the first AID system compatible with Senseonics Eversense® 365 one-year CGM twiist™ becomes the first AID system compatible with Senseonics Eversense® 365 one-year CGM

Senseonics Holdings earns a buy rating as Eversense 365 drives potential product-market fit and margin expansion. SENS's integration of Ascensia's commercial team and DTC investments is expected to boost revenue and gross margins above 50%. Q3 revenue grew 90% YoY, with a 42.8% gross margin and 55% YoY revenue growth guided for 2025.

Senseonics Holdings, Inc. ( SENS ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Tim Goodnow - President, CEO & Director Frederick Sullivan - CFO, Secretary & Treasurer Conference Call Participants Jeremy Feffer - Lifesci Advisors, LLC Matthew Miksic - Barclays Bank PLC, Research Division Joshua Jennings - TD Cowen, Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division Jayson Bedford - Raymond James & Associates, Inc., Research Division Xun Lee - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, everyone, and welcome to today's Senseonics Third Quarter 2025 Earnings Conference Call.

Senseonics Holdings (SENS) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.8 per share a year ago.

Senseonics (SENS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GERMANTOWN, Md., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2025 financial results after market close on Wednesday, November 5, 2025.

Preliminary unaudited revenue of $8.1 million for Q3 2025 Generated record quarterly new patient starts in Q3 2025 Established reverse stock split ratio of 1:20, anticipated to be effective October 17, 2025 GERMANTOWN, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced preliminary revenue for third quarter and provided a business update.

Senseonics Holdings, Inc. (NYSE:SENS ) Eversense 365 Commercial Update Conference Company Participants Tim Goodnow - President, CEO & Director Frederick Sullivan - CFO, Secretary & Treasurer Conference Call Participants Jeremy Feffer - Lifesci Advisors, LLC Brian Hansen - Ascensia Diabetes Care Us Inc. Matthew Miksic - Barclays Bank PLC, Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Joshua Jennings - TD Cowen, Research Division Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division Jayson Bedford - Raymond James & Associates, Inc., Research Division Xun Lee - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, everyone, and welcome to the Eversense 365 Commercial Update Call.

TOKYO--(BUSINESS WIRE)--PHC Holdings Corporation (President, Representative Director and CEO: Kyoko Deguchi, TSE: 6523) and its subsidiary Ascensia Diabetes Care, a global diabetes care company, today announced that Ascensia has signed a memorandum of understanding to transfer the commercial operations for Eversense® Continuous Glucose Monitoring (CGM) systems to Eversense maker Senseonics Holdings, Inc. (NYSE American: SENS). The companies are targeting to unite Eversense R&D, manufacturin.